Zacks Investment Research
10 Sept 2026, 22:50 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Adma Biologics is projected to report quarterly earnings of $0.19 per share, representing a year-over-year growth of 18.75%. — Strong projected earnings growth typically boosts investor confidence and can drive short-term price appreciation.
+0.30Adma Biologics' full-year revenue is projected at $536.82 million, a 5.22% increase from the prior year. — Steady revenue growth indicates business scaling, though the lower percentage relative to earnings suggests margin improvement rather than aggressive expansion.
+0.20Adma Biologics currently has a Forward P/E ratio of 12.17, which is a significant discount compared to the industry average of 20.54. — A lower P/E relative to peers suggests the stock may be undervalued, presenting a potential value opportunity for investors.
+0.15Continue reading
5 related stories
Search tags
Adma Biologics holds a Zacks Rank of #3 (Hold), with the Consensus EPS estimate remaining unchanged over the last 30 days. — A 'Hold' rating and stagnant estimates indicate a lack of new catalysts to drive the price in either direction.
+0.00Which stocks this story touches
The stock is down 1.01% and has trailed the S&P 500 and its sector over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
9h ago
